


SURVEY OF HEALTH PLAN COVERAGE OF GUIDELINE- AND EXPERT-RECOMMENDED TREATMENTS IN EOSINOPHILIC ESOPHAGITIS (EOE)



Terry Richardson, PharmD, BCACP¹, Maureen Bauer, MD², Drake Reiter, PharmD³, Zachary Contreras, PharmD⁴, Christine Radkey, PharmD⁵

BACKGROUND

Guideline- and expert-recommended treatment of EoE includes diet elimination therapy, proton pump inhibitors (PPIs), topical swallowed corticosteroids, elemental (amino acid) formula, and recently FDA-approved biologic therapy. Historically, most treatments were prescribed off-label or were available over the counter, leading to potential gaps in medication use history/claims data and therefore potential challenges in meeting coverage criteria for newer therapies.

OBJECTIVE

Gain regional insights from managed care professionals related to the implementation of guidelines and expert recommendations on EoE.

METHODS

A survey containing multiple-choice, open-ended, and Likert scale rating questions was fielded by Impact Education, LLC, from January to May 2024 to a network of managed care professionals from the AMCP Affiliates in California and Northwest (West), and Mid-Atlantic. All survey respondents were required to attest to having influence over formulary and/or other clinical management decisions within their organization.


CONCLUSIONS

Across both regional surveys, coverage for guideline- and expert-recommended treatments for EoE was consistent but somewhat limited. Coverage for biologics often requires a prior trial and failure of either a PPI or topical swallowed corticosteroid. The findings highlight the need to consider guidelines, expert recommendations, and existing coverage status of first-line therapies during coverage policy development for new treatments.

RESULTS

Across respondents from the West (n=33) and the Mid-Atlantic (n=48) regions, it was reported that their organizations represent over 145 million covered lives. Most respondents were pharmacists (West 88%, Mid-Atlantic 84%). The survey-reported coverage for PPIs for EoE was slightly higher in the Mid-Atlantic (65%) compared to the West (64%). For topical swallowed corticosteroids, coverage was more commonly reported in the Mid-Atlantic (51%) than in the West (45%). And coverage for elemental (amino acid) formulas was low in both the West (33%) and Mid-Atlantic (31%). The reported coverage for the FDA-approved biologic dupilumab was slightly higher in the West (55%) compared to the Mid-Atlantic (53%). A significant proportion of payers reported prior authorization (PA) criteria for dupilumab requiring a trial and failure of either a PPI or topical swallowed corticosteroids for coverage (West 73%, Mid-Atlantic 79%).


Respondent Demographics by Region



Respondents estimate their organizations represent over **145 million covered lives**





Coverage for Guideline- and Expert-Recommended Treatments in EoE by Region



Q: Does your organization provide coverage for PPIs, topical (swallowed) glucocorticoids, elemental (amino acid) formula, or dupilumab for patients with an EoE diagnosis?

*Use of asthma inhalers containing either budesonide or fluticasone that are administered to the esophagus by swallowing the medications (e.g., budesonide slurry, fluticasone MDI swallowed). The FDA approved the first oral budesonide suspension for EoE in February 2024, while these surveys were being collected.

Download  Listen 

Supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi.